6 cells). Phagocytosis by LAP macrophages was reduced ϳ40% compared to that of HC, and killing of periodontal pathogens, including Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, were similarly reduced. LAP neutrophils also displayed slower kinetics (ϳ30%) and decreased maximal phagocytosis (ϳ20% lower) with these pathogens than those of HC. The administration of MaR1 at 1 nM enhanced phagocytosis (31 to 65% increase), intracellular antimicrobial reactive oxygen species production (26 to 71% increase), bacterial killing of these periodontal pathogens (22 to 38% reduction of bacterial titers), and restored impairment of LAP phagocytes. Together, these results suggest that therapeutics targeting the Maresin pathway have clinical utility in treating LAP and other oral diseases associated with infection, inflammation, and altered phagocyte functions.
R
esolution of inflammation is an active process orchestrated by specialized proresolving lipid mediators (SPMs) derived from essential fatty acids (1) . During self-resolving inflammation, there is a temporal lipid mediator (LM) class switch from classic proinflammatory lipid mediators, such as leukotrienes (LT) and prostaglandins (PG), to SPMs that include lipoxins (LX), resolvins (Rv), protectins (PD), and maresins (MaR) (2, 3) . SPMs counterregulate acute inflammation via separate but related anti-inflammatory and proresolving actions in diverse experimental animal disease models in vivo (4) . Failure to resolve acute inflammation may result in chronic inflammation, fibrosis, tissue damage, and loss of organ function (1, 5) . It is well appreciated that uncontrolled inflammation is a unifying factor in the pathogenesis of several chronic inflammatory diseases, including cardiovascular, lung, joint (3) (4) (5) , and periodontal diseases (6) . Thus, dysregulated biosynthesis of proresolving lipid mediators may underlie part of the pathogenesis of uncontrolled inflammation (1) and oral inflammation (6) .
Localized aggressive periodontitis (LAP) is a clinically distinct form of rapidly progressing periodontal disease linked to abnormal leukocyte-mediated tissue destruction with infection and uncontrolled inflammation (7) . The sites with periodontal pockets in LAP patients harbor higher levels of periodontal pathogens, including Porphyromonas gingivalis (8) and Aggregatibacter actinomycetemcomitans (9, 10) . Earlier results indicate that activated peripheral blood from LAP patients exhibits an imbalanced lipid mediator profile with higher production of proinflammatory mediators, including leukotriene B 4 (LTB 4 ; 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid), and lower levels of proresolving mediators, including lipoxin A 4 (LXA 4 ; 5S,6R,15S-trihydroxyeicosa-7E,9E,11Z,13E-tetraenoic acid). Of note, levels of 14-hydroxy-docosahexaenoic acid (14-HDHA; 14S-hydroxy-4Z,7Z,10Z,12E,16Z,19Z-DHA), a marker of the Maresin 1 biosynthetic pathway, are reduced in activated peripheral blood from LAP patients compared to those from healthy control donors (11, 12) . Therefore, LAP may serve as a model human disease to investigate the biosynthesis and actions of Maresin 1 in resolving inflammation and infection.
Maresin 1 (MaR1) was first identified in macrophages as a potent proresolving lipid mediator (12) and recently was identified in several human tissues (13) . Total organic synthesis was achieved, and the complete stereochemistry of bioactive MaR1 was established as 7R,14S-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid (14) . In addition to its proresolving actions, MaR1 also promotes tissue regeneration and relieves inflammatory neuropathic pain (14) . Along these lines, we recently cloned human macrophage 12-lipoxygenase (12-LOX) that proved identical to the human platelet 12-LOX in nucleotide sequence and demonstrated its initiating role in MaR1 biosynthesis (15, 16) . In the present study, we investigated the MaR1 biosynthetic pathway in leukocytes from LAP patients and its role in regulating phagocyte functions in the containment and killing of periodontal pathogens.
MATERIALS AND METHODS
Human samples. Human samples were obtained following informed consent approved by the Forsyth Institute Review Board (FIRB) (protocol number 11-05). Venous blood (ϳ60 ml; 25 U/ml heparin) was collected from patients with a diagnosis of localized aggressive periodontitis (LAP) according to the American Academy of Periodontology (AAP) guidelines (17) and from age-and gender-matched healthy volunteers (HC) with no signs of periodontal disease. All blood donors otherwise were healthy nonsmokers and had denied taking any nonsteroidal anti-inflammatory drugs (NSAIDs) for at least 2 weeks prior to the experiment. LAP subjects usually aggregate in families and present with severe, early-onset bone loss around first molars and incisor teeth (17, 18) . The LAP patient cohort was characterized by a hyperresponsive neutrophil phenotype (elevated LTB 4 and IL-8-induced superoxide generation) (18) . The patients were diagnosed by a licensed periodontist (H. Hasturk) in the Center for Clinical and Translational Research at the Forsyth Institute. In addition, macrophages were prepared from peripheral blood monocytes donated from healthy human volunteers at the Children's Hospital, Boston, for independent experiments, including the dose response of MaR1 in enhancing macrophage phagocytosis and intracellular reactive oxygen species (ROS) generation as described below.
Human neutrophil and monocyte isolation and macrophage culture. Neutrophils and peripheral blood mononuclear cells (PBMCs) were separated from human whole blood by Ficoll-Histopaque density gradient centrifugation (Histopaque 1077 and 1119; Sigma-Aldrich). Neutrophils were isolated after isotonic lysis of red blood cells followed by two washes in phosphate-buffered saline (Sigma-Aldrich). Monocytes were obtained after adhesion purification and incubated with RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Life Technologies) in the presence of human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF; R&D Systems) (20 ng/ml, 7 days, 37°C, pH 7.4) for macrophage differentiation, which were used throughout the experiments unless otherwise specified. For lipid mediator metabololipidomics (13) , monocytes were cultured in phenol red-free RPMI 1640 medium supplemented with 10% human serum (Lonza) as described previously (14) .
Oral bacterial preparation. Porphyromonas gingivalis (A7436) was cultured on 2% Trypticase soy agar (TSA) supplemented with 2.6% brain heart infusion agar (BD BBL), 1% (wt/vol) yeast extract (BD Bacto), 5% defibrinated sheep red blood cells (Northeast Laboratory Services), 5 g/ml of hemin, and 0.5 g/ml vitamin K (Sigma-Aldrich). Aggregatibacter actinomycetemcomitans (ATCC Y4), Fusobacterium nucleatum subsp. nucleatum (ATCC 25586), and Streptococcus intermedius (ATCC 27335) were grown on TSA plates (BD Diagnostic Systems). All cultures were placed in an anaerobic chamber (85% N 2 , 10% CO 2 , 5% H 2 at 37°C). Colonies were transferred from the plate to respective broth media, namely, P. gingivalis into Wilkin's broth (Oxoid) and the others into brain heart infusion broth (BD BBL), and grown for 4 days. Bacterial titers were determined at 600 nm using a spectrometer (SmartSpec 3000; Bio-Rad) and adjusted to an OD of 1.0 (approximately 10 9 CFU/ml) prior to experiments.
Expression of surface markers and 12-LOX in human macrophages. Macrophages from LAP patients and HC were harvested, fixed, and stained with CD54, CD206, and HLA-DR antibodies (Ab) (clones HCD54, 19.2, and G46-6; BD Biosciences). For 12-lipoxygenase (12-LOX) expression, intracellular staining was carried out using rabbit antihuman 12-LOX Ab (Novus) and Alexa Fluor-conjugated goat anti-rabbit Ab (Jackson) after cell permeabilization (Cytofix/Cytoperm; BD Biosciences) as described previously (16) . Expression levels of the proteins were monitored by flow cytometry (FACSCanto II; BD Biosciences) and analyzed with FlowJo (TreeStar).
LC-MS/MS-based LM metabololipidomics. All samples for liquid chromatography-tandem mass spectroscopy (LC-MS/MS) analysis were subjected to solid-phase extraction (13) . Briefly, 1-ml macrophage incubations were stopped by adding two volumes of ice-cold methanol with deuterium-labeled internal standards d 8 -5S-hydroxyeicosatetraenoic acid, d 4 -leukotriene B 4 , d 5 -lipoxin A 4 , d 5 -resolvin D2, and d 4 -prostaglandin E 2 (500 pg each) to facilitate quantification and sample recovery. Supernatants were loaded onto a C 18 column following centrifugation and protein precipitation. LMs were eluted with the methyl formate fraction, dried, and resuspended in methanol-water (50:50, vol/vol) prior to injection into the LC-MS/MS system QTrap 6500 (ABSciex), as detailed previously (13) .
Maresin 1 preparation. MaR1 was prepared by total organic synthesis as described in reference 14 as part of the NIH Program Project P01-GM095467 (C. N. Serhan), and additional MaR1 for these experiments was purchased from Cayman Chemical. The compound was validated with LC-MS/MS and the concentration calibrated using UV absorption at a maximum wavelength of 271 nm before experiments.
Macrophage and neutrophil phagocytosis in vitro. GM-CSF-differentiated human macrophages (5 ϫ10 4 cells/well) or neutrophils (10 5 cells/well) were adhered onto 96-well plates and incubated with vehicle (phosphate-buffered saline containing Ca 2ϩ and Mg 2ϩ , termed PBS ϩ/ϩ ; Sigma-Aldrich) or the indicated concentration of MaR1 for 15 min, followed by incubation with fluorescence-labeled bacteria (BacLight Green; Molecular Probes) (phagocyte-to-bacterium ratio, 1:50) or fluorescent microspheres (FluoSpheres; Molecular Probes) (phagocyte-to-particle ratio, 1:10) for the indicated time (15 min to 3 h). Plates were washed 3 times with PBS ϩ/ϩ , extracellular fluorescence was quenched by Trypan blue (1:15 dilution), and phagocytosis was determined by a SpectraMax M3 fluorescent plate reader (Molecular Devices). For direct comparison of macrophage phagocytosis between LAP patients and HC, macrophages (2 ϫ 10 4 cells/well) were used under essentially the same conditions as those described above and subjected to flow cytometry to determine the mean florescence intensity (MFI).
Macrophage and neutrophil intracellular reactive oxygen species generation. Macrophages (5 ϫ10 4 cells/well) and neutrophils (10 5 cells/ well) were preincubated with the fluorescent intracellular ROS indicator carboxy-H 2 DCF-DA (reactive oxygen species detection reagents; Invitrogen) for 30 min and washed. The cells then were incubated with vehicle (PBS ϩ/ϩ ; pH 7.4) or the indicated concentration of MaR1 for 15 min, followed by the addition of bacteria (phagocyte-to-bacterium ratio, 1:50) for 1 h. Intracellular ROS generation was determined using a SpectraMax M3 fluorescent plate reader (Molecular Devices).
Transmission electron microscopy (TEM). Freshly isolated neutrophils (10 6 cells) from LAP patients and HC were incubated with P. gingivalis (polymorphonuclear leukocyte [PMN]-to-bacterium ratio of 1:50) for 1 h; cells were fixed with formaldehyde-glutaraldehyde-picric acid (FGP) and submitted to the Electron Microscopy Core Facility (Harvard Medical School) for further processing and analysis.
Bacterial killing by macrophages. Macrophages (5 ϫ 10 4 cells/well) from HC and LAP patients were incubated with the indicated concentration of MaR1 for 15 min, followed by the addition of bacteria (macrophage-to-bacterium ratio of 1:50) for 60 min. Supernatant was gently mixed, diluted with PBS, and plated (50 l) onto respective agar plates to determine bacterial titers. Photos were taken after 7 days, and CFU were counted using ImageJ (NIH).
Statistical analysis. Results are expressed as means Ϯ standard errors of the means (SEM). Statistical analysis was performed using Student's t test (two independent groups) and one-way analysis of variance (ANOVA) (multiple groups). A P value of Յ0.05 was considered significant.
RESULTS
Macrophages from LAP patients display lower 12-lipoxygenase and reduced endogenous MaR1. Since human 12-LOX is the key initiating enzyme in the biosynthesis of MaR1 (15, 16) (Fig. 1A) , we first investigated the levels of 12-LOX in macrophages from LAP patients. These LAP macrophages exhibited significantly lower 12-LOX levels (ϳ30% reduction) than healthy control (HC) subjects (Fig. 1B) . We next identified and quantified the endogenous levels of MaR1 and its biosynthetic pathway marker, 14-HDHA, in LAP and HC macrophage incubations using LC-MS/MS-based LM-metabololipidomics. Representative multiple reaction monitoring (MRM) chromatograms and MS/MS spectra for the identification of MaR1 are shown in Fig. 1C and D. MaR1 levels were significantly lower in the LAP macrophages than in HC (87.8 Ϯ 50 pg/10 6 cells versus 239.1 Ϯ 32 pg/10 6 cells; ϳ65% reduction), with a reduction in its pathway marker, 14-HDHA (625 Ϯ 251 pg/10 6 cells versus 935 Ϯ 217 pg/10 6 cells; ϳ30% reduction), that was not statistically significant (Fig. 1E) . Taken together, these findings suggested that in LAP macrophages MaR1 biosynthesis is dysregulated.
MaR1 restores impaired phagocytosis of P. gingivalis and A. actinomycetemcomitans in LAP patient macrophages. Because macrophage clearance of bacteria is critical to control infection and resolution (2, 3) and MaR1 enhances macrophage phagocytosis of zymosan and apoptotic PMN (12, 14) , we questioned whether MaR1 could enhance the phagocytosis of two periodontal pathogens, namely, P. gingivalis and A. actinomycetemcomitans. Indeed, MaR1 dose dependently (10 pM to 100 nM) enhanced the phagocytosis of both bacteria (ϳ10 to 35% above vehicle) by macrophages from healthy donors ( Fig. 2A ). Since macrophages from LAP patients had lower MaR1 levels, we next investigated their ability to phagocytize these periodontal pathogens. Macrophages from LAP patients exhibited an approximately 40% reduction in phagocytosis of both P. gingivalis and A. actinomycetemcomitans compared to the levels for HC at 1 h and a similar ratio at 3 h (Fig.  2B ). When MaR1 (0.1 to 10 nM) was incubated with macrophages from LAP patients, a statistically significant increase in phagocytosis of P. gingivalis (ϳ37% at 1 nM) and A. actinomycetemcomitans (ϳ65% at 1 nM) was observed, reaching levels that were comparable to those obtained with macrophages from HC (Fig.  2C ). These results demonstrate that MaR1 enhances macrophage phagocytosis of P. gingivalis and A. actinomycetemcomitans, rescuing the phagocytic function that also was observed to be impaired in macrophages from LAP patients.
MaR1 rescues impaired LAP macrophage clearance of both P. gingivalis and A. actinomycetemcomitans by enhancing intracellular antimicrobial ROS. We next determined if macrophages from LAP patients have diminished bacterial killing. For these experiments, live bacteria were incubated with macrophages from HC and LAP patients, and the supernatants were collected and cultured to determine bacterial titers. Supernatants from LAP macrophages gave higher bacterial titers of both P. gingivalis (26% higher) and A. actinomycetemcomitans (14% higher) than macrophages from HC (Fig. 3) . The incubation of macrophages from HC and LAP patients with MaR1 (1 nM) significantly reduced bacterial titers of both of P. gingivalis and A. actinomycetemcomi- tans. Since MaR1 enhanced macrophage uptake and clearance of these pathogens, we next questioned whether LAP macrophages produce less intracellular ROS following the engulfment of these bacteria (18, 19) and whether MaR1 could enhance ROS production. To address this, macrophages were incubated with a fluorescent intracellular ROS indicator followed by P. gingivalis and A. actinomycetemcomitans in the presence of either MaR1 or vehicle (see Materials and Methods for details). MaR1 dose dependently enhanced macrophage intracellular ROS generation with both pathogens (see Fig. S1A in the supplemental material). Intracellular ROS levels in macrophages from HC and LAP patients without bacteria were not statistically different (see Fig. S1B, inset) . The addition of bacteria resulted in an ϳ20 to 30% increase in intracellular ROS. MaR1 (1 nM) enhanced intracellular ROS production in both HC and LAP macrophages with greater increases in incubations with A. actinomycetemcomitans (33% increase above vehicle) than with P. gingivalis (see Fig. S1B ). These results indicated that intracellular ROS production is not reduced in LAP macrophage and that MaR1 further increases ROS in both LAP and HC macrophage when incubated with oral pathogens (P. gingivalis and A. actinomycetemcomitans).
Neutrophils from LAP patients display generalized impairment in phagocytosis. Since neutrophils play an important role in the pathogenesis of LAP (7, 18), we next investigated whether neutrophils from the LAP patients also display impaired phagocytosis of P. gingivalis and A. actinomycetemcomitans. By incubating fluorescence-labeled bacteria with the neutrophils, it was apparent that LAP neutrophils exhibited impaired phagocytosis, with slower kinetics from 0 to 2 h and reduced maximal phagocytosis (Fig. 4A) . We next questioned whether this abnormality is specific to certain bacteria by testing F. nucleatum, S. intermedius, and latex particles. LAP neutrophils all gave reduced phagocytosis (Fig. 4B) . We next determined whether LAP neutrophils exhibited (Fig. 4C) . Similar results were obtained when we assessed the extent of phagocytosis at 60 min, revealing that LAP neutrophils phagocytized significantly less F. nucleatum than S. intermedius compared to phagocytosis by HC (Fig. 4D) . We also found reduced maximal phagocytosis with LAP neutrophils, with a 46% reduction in F. nucleatum and ϳ20% reduction in the extent of phagocytosis for other bacteria assessed compared to values obtained with HC neutrophils (Fig. 4D) . These results indicate that LAP neutrophils, compared to HC, display generalized impairment in phagocytosis, yet a differential response may exist for F. nucleatum.
MaR1 partially restores LAP neutrophil phagocytosis of P. gingivalis and A. actinomycetemcomitans. We next questioned whether MaR1 could act on neutrophils to rescue phagocytic functions in neutrophils from LAP patients. The incubation of neutrophils with MaR1 dose dependently enhanced neutrophil phagocytosis of P. gingivalis (ϳ42% increase above vehicle at 1 nM) and A. actinomycetemcomitans (ϳ46% increase above vehicle at 1 nM) with both LAP and HC neutrophils (Fig. 5) and partially restores the defect in LAP neutrophils above 1 pM concentrations. In addition, MaR1 dose dependently enhanced both LAP and HC neutrophil intracellular ROS generation with both pathogens (see Fig. S3 in the supplemental material). These results indicated that MaR1 enhances neutrophil intracellular ROS generation and partially restores LAP neutrophil-impaired phagocytosis of P. gingivalis and A. actinomycetemcomitans.
Given the impaired phagocytosis of neutrophils from LAP patients, samples were taken for inspection using TEM. No apparent structural differences were observed between LAP and HC neutrophils or their phagocytic apparatus. Representative TEM images of LAP neutrophils after incubation with P. gingivalis are shown (Fig. 5) .
DISCUSSION
In the present study, we investigated macrophage biosynthesis of MaR1 in cells from LAP patients using LM metabololipidomics and assessed the action of MaR1 in regulating phagocyte functions. We found that in cells from LAP patients, MaR1 biosynthesis is dysregulated and that their phagocytes (neutrophils and macrophages) display an impaired ability to phagocytize and kill the periodontal pathogens P. gingivalis and A. actinomycetem- comitans. Exogenous MaR1 partially restored this impairment in LAP neutrophils and macrophages, increasing intracellular ROS production, phagocyte ingestion, and clearance of the periodontal pathogens. In parallel incubations, MaR1 also enhanced these functions in phagocytes from healthy controls.
Maresin 1 biosynthesis in humans was established recently using recombinant human macrophage 12-LOX enzyme and synthetic intermediates (15, 16) . It was demonstrated that 12-LOX is the key initiating enzyme that produces 14S-hydroperoxydocosahexaenoic acid (14S-HpDHA) from the precursor docosahexaenoic acid (DHA) (15) , which is known to be selectively stored in human and other mammalian tissues, including neural and lymphoid tissues (20, 21) . The intermediate 14S-HpDHA then is converted via 12-LOX-mediated epoxidation to 13S,14S-epoxy-docosahexaenoic acid (13,14-epoxy-maresin; 13,14-eMaR), which is further converted to MaR1 by human macrophages (16) (Fig. 1A ). 14-HpDHA also could be enzymatically reduced to 14-HDHA, the corresponding alcohol, which can be used as a marker of the Maresin biosynthetic pathway (12) and was reported to be lower in activated LAP whole blood (11) . In the present experiments, we found that macrophages from LAP patients have lower 12-LOX (ϳ70%) and reduced levels of 14-HDHA (ϳ70%), as well as MaR1 (ϳ35%), compared to those of cells from healthy control donors (Fig. 1B and E) . These results suggest that the MaR1 biosynthetic pathway is diminished in leukocytes in patients with localized aggressive periodontitis.
Bacterial clearance is critical for containing infection and its resolution, and MaR1 enhances macrophage phagocytosis of both zymosan and apoptotic PMN (12, 14) ; therefore, in the present study we assessed whether MaR1 could specifically enhance phagocytosis and clearance of the periodontal pathogens P. gingivalis and A. actinomycetemcomitans. MaR1 enhanced the phagocytosis of both bacteria in the concentrations identified from endogenous production (Fig. 1E) . This observation led us to question whether LAP macrophages with lower levels of MaR1 exhibit impaired phagocytosis of these pathogens. Earlier, it was discovered that LAP neutrophils display defective phagocytosis of Staphylococcus aureus (22, 23) . Recently, macrophages from LAP patients also were found to display impaired phagocytosis of zymosan that was rescued with Resolvin E1 (11) . It was unknown whether these phagocytes also display reduced phagocytosis of periodontal pathogens. In the present report, we found impaired phagocytosis of both P. gingivalis and A. actinomycetemcomitans by phagocytes (neutrophils and macrophages) from LAP patients ( Fig. 2B and 4A ). Of note, LAP macrophages did not express different levels of surface markers for polarized phenotypes (CD54, CD2016, and HLA-DR; n ϭ 4 paired donors; data not shown). The incubation of HC and LAP macrophages with periodontal pathogens (cell-to-bacterium ratio of 1:50) for 1 h did not initiate higher levels of MaR1. Instead, the levels of MaR1 were reduced similarly in both HC and LAP macrophages, indicating the pathogens did not alter the biosynthesis differently between the two groups, and MaR1 may be rapidly metabolized or its biosynthesis inhibited under these conditions (see Fig. S5 in the supplemental material). Importantly, the addition of exogenous MaR1 normalized the impaired phagocytosis in LAP phagocytes and enhanced the clearance ability of LAP macrophages (Fig. 2C, 3, and 5) .
It is now widely appreciated that periodontal disease is a polymicrobial infection modulated by host response (24) . Besides P. gingivalis and A. actinomycetemcomitans, there is a growing body of evidence implicating the potential role of other commensal oral bacteria in the biofilm. S. intermedius is a Gram-positive, faculta- tive anaerobic commensal oral bacterium that has an antagonistic relationship with periodontal pathogens like P. gingivalis and A. actinomycetemcomitans (previously known as Bacteroides gingivalis and Actinobacillus actinomycetemcomitans in the literature [25] ). Additionally, F. nucleatum recently has been implicated as a potential target pathogen (26) . F. nucleatum also is prevalent within deep periodontal pockets of LAP patients (27) , and its abundance in the biofilm is associated with the severity of periodontal inflammation in adolescents (28) . In addition, F. nucleatum is essential for the growth of P. gingivalis and A. actinomycetemcomitans (29) , and it can synergistically create a stronger inflammatory response with more tissue destruction in coinfections with P. gingivalis in a mouse periodontitis model (30) . In the current study, we investigated LAP neutrophil phagocytosis of four oral bacteria and compared results to those for HC. The LAP neutrophils exhibited generalized impairment in the phagocytosis of each of the four bacteria, giving lower rates of phagocytosis and reduced maximal phagocytosis. The most prominent deficiency was in the extent of phagocytosis of F. nucleatum (42% reduction), followed by A. actinomycetemcomitans (27% reduction), P. gingivalis (24% reduction), and S. intermedius (18% reduction), compared to that of HC after 1 h of incubation (Fig. 4C) . It was reported earlier that LAP neutrophils exhibit 10 to 20% reduced phagocytosis of Staphylococcus aureus at 1 h, which also coincided with the reduced rate of phagocytosis (23) . In addition, the reduction in maximal phagocytosis with LAP neutrophils is also about 20% for the oral bacteria tested here, except for F. nucleatum at 46%. The results suggest that F. nucleatum plays an important role in dysbiosis (31) in patients with localized aggressive periodontitis, and the imbalanced kinetics suggest a mechanism for hostmediated disruption of biofilm homeostasis. Of note, in our experiments MaR1 enhanced the macrophage phagocytosis of F. nucleatum (ϳ30% increase at 1 nM) with cells from healthy donors (see Fig. S4 in the supplemental material).
Following phagocytosis, intracellular ROS generation is critical for oxidative bacterial killing within the phagocytes (19) . Earlier, our group demonstrated that resolvins D1 and D2 (RvD1 and RvD2) and Protectin (PD1) increase intracellular ROS generation during human PMN ingestion of Escherichia coli (32, 33) . In the present study, we report that MaR1 enhanced the phagocytosis of P. gingivalis and A. actinomycetemcomitans and also increased intracellular ROS generation within phagocytes from both HC and LAP (see Fig. S1 to S3 in the supplemental material). In addition, LAP neutrophils and macrophages produced levels of intracellular ROS similar to those of HC when incubated with both pathogens. However, under the same conditions, fewer bacteria were ingested by the LAP phagocytes, indicating that LAP phagocytes present with hyperresponsive intracellular ROS generation. It was reported earlier that LAP neutrophils release higher levels of extracellular ROS after activation (17) , which is counterregulated and reduced by Resolvin E1 (RvE1) and aspirin-triggered lipoxin analog, members of other families of proresolving lipid mediators biosynthesized from eicosapentaenoic acid (EPA) and arachidonic acid (AA) (34) . Topical RvE1 resolves inflammation and restores tissue homeostasis in a rabbit P. gingivalis-infected periodontitis model, demonstrating its protective role (35) .
Taking our results together, we identified for the first time several functional defects in phagocytes obtained from LAP patients. They displayed impaired bacterial containment and killing along with reduced MaR1 production in the macrophages. The exogenous administration of MaR1 partially corrected this defect, enhancing the phagocytosis and killing of periodontal pathogens as well as stimulating intracellular ROS generation. Moreover, these results suggest that the MaR1 biosynthetic pathway underlies some of the pathogenesis in LAP and that new therapeutics targeting this Maresin biosynthetic and related pathways may have clinical utility in treating localized aggressive periodontitis and other oral diseases associated with bacterial infection, uncontrolled inflammation, and failed resolution.
